1.Is There a Role of Pharmacological Treatments in the Prevention or Treatment of Osteonecrosis of the Femoral Head?: A Systematic Review
Yun Jong LEE ; Quanjun CUI ; Kyung Hoi KOO
Journal of Bone Metabolism 2019;26(1):13-18
BACKGROUND: Various pharmacological treatments have been suggested to treat osteonecrosis of the femoral head. However, their practicability remains a controversial issue. METHODS: We systemically reviewed articles published during last 20 years to assess the efficacy and safety of the pharmacological treatments. RESULTS: To date, enoxaparin, statins, bisphosphonates, iloprost and acetylsalicylic acid have been practiced for the treatment of osteonecrosis. However, none of them were proven to be effective by high level studies, and most of them have adverse reactions. CONCLUSIONS: No pharmacological prevention or treatment of osteonecrosis is recommendable at this moment.
Aspirin
;
Bone Remodeling
;
Diphosphonates
;
Drug Therapy
;
Enoxaparin
;
Head
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Iloprost
;
Osteonecrosis
2.The Therapeutic Effect of Inhaled Iloprost in Newborn Infants with Severe Persistent Pulmonary Hypertension Refractory to Inhaled Nitric Oxide.
Yoon Ki HAN ; Soon Min LEE ; Ho Seon EUN ; Jeong Eun KIM ; Ran NAMGUNG ; Min Soo PARK ; Kook In PARK ; Chul LEE
Korean Journal of Perinatology 2011;22(1):57-63
Inhaled iloprost, a stable carbacyline derivative of prostacyclin, has been used recently for the treatment of adults with pulmonary hypertension but only few reports are available about its use in neonatal critical care. We report therapeutic trial of inhaled iloprost in newborn infants with persistent pulmonary hypertension of the newborn (PPHN) who did not respond to inhaled nitric oxide (iNO). Inhaled iloprost (Ventavis(R), Bayer Shering Pharma, Germany) was effective in neonates with severe PPHN who showed inadequate response to iNO. We suggest that inhaled iloprost could be considered as an additional therapeutic option in PPHN refractory to iNO.
Adult
;
Critical Care
;
Epoprostenol
;
Humans
;
Hypertension, Pulmonary
;
Iloprost
;
Infant, Newborn
;
Nitric Oxide
3.Efficacy of Inhaled Iloprost in Cor Pulmonale and Severe Pulmonary Hypertension Associated with Tuberculous Destroyed Lung.
Yae Min PARK ; Wook Jin CHUNG ; Sang Pyo LEE ; Deok Young CHOI ; Han Joo BAEK ; Sung Hwan JUNG ; In Suck CHOI ; Eak Kyun SHIN
Journal of Cardiovascular Ultrasound 2014;22(2):95-97
Chronic obstructive pulmonary disease (COPD) is one of the causes of cor pulmonale. Cor pulmonale patients with pulmonary hypertension have a significant lower survival rate than patients without. However, there is no conclusive treatment options in cor pulmonale and pulmonary hypertension associated with COPD until now. We report a patient with cor pulmonale and pulmonary hypertension associated with severe form of COPD and tuberculous destroyed lung who achieved marked clinical, functional and echocardiographic hemodynamic improvements with inhaled iloprost for six months.
Echocardiography
;
Hemodynamics
;
Humans
;
Hypertension, Pulmonary*
;
Iloprost*
;
Lung*
;
Pulmonary Disease, Chronic Obstructive
;
Pulmonary Heart Disease*
;
Survival Rate
4.Diagnosis and treatment of idiopathic pulmonary arterial hypertension.
Korean Journal of Medicine 2006;71(1):4-9
Idiopathic pulmonary arterial hypertension (previous primary pulmonary hypertension) was a progressive disease with high mortality. Many patients with idiopathic pulmonary arterial hypertension did not show vasoreactivity, rapidly resulted in marked disability, right heart failure and death. Recent advances of therapeutic modalities have revolutionized the treatment of idiopathic pulmonary arterial hypertension. Irrespective of pulmonary arterial vasoreactivity, new vasodilatng agents, such as epoprostenol, treprostinil, iloprost, bosentan, and sildenafil, significantly improved hemodynamics, symptoms, exercise capacities, quality of life, and survival. The median survival of patients with idiopathic pulmonary arterial hypertension has been prolonged from 2.8 years to more than 5 years. In a near future, pulmonary arterial hypertension could be easily controlled like a systemic arterial hypertension.
Diagnosis*
;
Epoprostenol
;
Heart Failure
;
Hemodynamics
;
Humans
;
Hypertension*
;
Iloprost
;
Mortality
;
Quality of Life
;
Sildenafil Citrate
5.Pulmonary Arterial Hypertension is Normalized Following Six Years of Inhaled Iloprost Treatment in a Patient with Systemic Sclerosis.
So Young YOON ; Eun Soo YOO ; Eun Jung YOO ; Ju Yang JUNG ; Hyoun Ah KIM ; Chang Hee SUH
Journal of Rheumatic Diseases 2017;24(2):114-118
Pulmonary arterial hypertension is a critical manifestation of systemic sclerosis (SSc) and is a main cause of death. Several treatment modalities for SSc have been identified, with effects that improve quality of life and mortality rates. However, whether these drugs can also normalize pulmonary arterial pressure, remains unclear. Here, we report the case of a woman with diffuse SSc with pulmonary arterial hypertension, who had a functional status equivalent to the New York Heart Association class III. The patient was treated with inhaled iloprost. After six years of inhaled iloprost therapy, echocardiography showed that pulmonary arterial pressure normalized, accompanied by improvement in functional capacity. Inhaled iloprost might not only normalize pulmonary arterial pressure, but also improve the functional status of patients with SSc with pulmonary arterial hypertension.
Arterial Pressure
;
Cause of Death
;
Echocardiography
;
Female
;
Heart
;
Humans
;
Hypertension*
;
Hypertension, Pulmonary
;
Iloprost*
;
Mortality
;
Quality of Life
;
Scleroderma, Systemic*
6.A case of persistent pulmonary hypertension of the newborn: Treatment with inhaled iloprost.
Yoon Young JANG ; Hye Jin PARK
Korean Journal of Pediatrics 2009;52(10):1175-1180
We report a case of a full-term neonate with persistent pulmonary hypertension who developed asphyxia after birth and was treated with iloprost. The neonate had persistent hypoxia and did not respond to supportive treatment. Because inhaled nitric oxide (iNO) was not available in our hospital, inhaled iloprost was administered via an endotracheal tube. This resulted in an immediate elevation of oxygen saturation. Echocardiography revealed the conversion of the right-to-left ductal shunt to the left-to-right one and a decrease of the right ventricular pressure. The use of inhaled iloprost did not cause any significant side effects. Here, we describe our experience where iloprost was used in a neonate with persistent pulmonary hypertension because the standard therapy with inhaled nitric oxide was not available.
Anoxia
;
Asphyxia
;
Echocardiography
;
Female
;
Humans
;
Hypertension, Pulmonary
;
Iloprost
;
Infant, Newborn
;
Nitric Oxide
;
Oxygen
;
Parturition
;
Persistent Fetal Circulation Syndrome
;
Ventricular Pressure
7.Acute responses to inhalation of Iloprost in patients with pulmonary hypertension.
Hong-Liang ZHANG ; Zhi-Hong LIU ; Yong WANG ; Chang-Ming XIONG ; Xin-Hai NI ; Jian-Guo HE ; Qin LUO ; Zhi-Hui ZHAO ; Qing ZHAO ; Xing-Guo SUN
Chinese Medical Journal 2012;125(16):2826-2831
BACKGROUNDIloprost has been used to test acute pulmonary vasoreactivity in idiopathic pulmonary arterial hypertension (PAH). We aimed to investigate the acute hemodynamic and oxygenation responses and tolerability to 20 µg aerosolized Iloprost in Chinese patients with pulmonary hypertension.
METHODSBetween March 2005 and May 2010, 212 pulmonary hypertension patients inhaled a single dose of 20 µg Iloprost over 10 - 15 minutes for vasoreactivity testing. The acute hemodynamic and oxygenation responses and adverse events were recorded.
RESULTSIloprost decreased total pulmonary resistance ((1747 ± 918) dyn×s×cm(-5) vs. (1581 ± 937) dyn×s×cm(-5), P < 0.001), increased stroke volume ((45.0 ± 22.1) ml vs. (47.0 ± 24.2) ml, P = 0.002), and cardiac output ((3.7 ± 1.7) L/ml vs. (3.9 ± 1.9) L/min, P = 0.009). Heart rate and systemic vascular resistance remained stable during inhalation. However, systemic arterial blood oxygen saturation fell slightly ((91.0 ± 6.8)% vs. (90.3 ± 6.7)%, P = 0.002). Pulmonary and systemic arterial blood pressures declined within 1 - 3 minutes after inhalation initiation and reached their lowest levels within 10 - 15 minutes. Idiopathic PAH responded more favorably than pulmonary hypertension due to other causes (P £0.001) and patients with less severe pulmonary hypertension have better responses to Iloprost. No adverse events requiring medical care or leading to termination of inhalation occurred.
CONCLUSIONSInhalation of 20 µg Iloprost showed potent and selective pulmonary hemodynamic effects and was well tolerated in the Chinese pulmonary hypertension patients. Patients with idiopathic PAH and less severe pulmonary hypertension responded more favorably to inhalation of Iloprost.
Administration, Inhalation ; China ; Hemodynamics ; drug effects ; Humans ; Hypertension, Pulmonary ; drug therapy ; Iloprost ; administration & dosage ; adverse effects ; therapeutic use
8.Challenges in the management of concomitant TB arthritis and AVN in a lupus patient with adverse drug reaction to anti-Koch's medications.
Tee Kenneth D. ; Magbitang Angeline-Therese D. ; Tee Michael L.
Philippine Journal of Internal Medicine 2014;52(4):189-192
BACKGROUND: Non traumatic osteonecrosis also known as avascular necrosis (AVN),and tuberculous arthritis (TB arthritis)most commonly present as chronic monoarticular conditions. Corticosteroid intake is known to predispose individuals to the development of these two conditions.
In AVN, corticosteroid remains to be the most common cause that leads to a final common pathway of disrupting blood supply to segments of bone causing cell death. In TB arthritis, corticosteroid renders a patient relatively immunocompromised predisposing to this extrapulmonary infection.
The incidence of tubercular osteonecrosis in a patient with systemic lupus erythematosus is rare. A review of literature only showed one case report of tubercular osteonecrosis diagnosed by aspiration cytology. Since tuberculosis (TB) is a destructive but curable disease, early diagnosis and treatment are essential.
OBJECTIVE: To present a case of tubercular osteonecrosis in a patient with systemic lupus erythematosus treated with anti-Koch's regimen and iloprost infusion.
CASE: A 27-year old Filipino female who was diagnosed with lupus nephritis and underwent three days methylprednisolone pulse therapy. Lupus nephritis improved and was clinically inactive for two years. She developed insidious onset of intermittent pain on her left knee, associated with swelling for four months with subsequent right hip pain of one week duration. MRI of the left knee showed osteonecrosis and arthritis. Radiograph of the right hip showed osteonecrosis. She underwent arthrocentesis of the left knee and the synovial fluid tested positive for tuberculosis by PCR. We started the patient on quadruple anti-Koch's regimen together with iloprost infusion which afforded clinical improvement.
CONCLUSION: To our knowledge, this is the first reported case of a lupus patient with concomitant polyarticular osteonecrosis complicated by monoarticular tuberculous arthritis. Medical treatment, while it may be complicated by adverse drug events, is effective in symptomatic treatment, but a multidisciplinary approach is suggested for optimal outcome.
Human ; Female ; Adult ; Adrenal Cortex Hormones ; Arthritis ; Arthrocentesis ; Cell Death ; Early Diagnosis ; Iloprost ; Incidence ; Lupus Erythematosus, Systemic ; Lupus Nephritis ; Methylprednisolone ; Osteonecrosis ; Pain ; Polymerase Chain Reaction ; Tuberculosis, Osteoarticular
9.Effects of hyperbaric oxygen and iloprost on intestinal ischemia-reperfusion induced acute lung injury.
Annals of Surgical Treatment and Research 2019;96(1):34-40
PURPOSE: To research the effects of iloprost (IL) and hyperbaric oxygen (HBO) combination treatment on lung injury and on tumor necrosis factor alpha (TNF-α), myeloperoxidase (MPO), malondialdehyde (MDA), and soluble intercellular adhesion molecule-1 (sICAM-1) levels after tissue or organ ischemia-reperfusion, and on ischemia-reperfusion induced lung neutrophil sequestration. METHODS: Forty white New Zealand rabbits were assigned randomly into 5 groups: HBO, IL, HBO+IL, control, and sham groups. TNF-α values were checked before ischemia, in the 1st hour of ischemia and in the 1st and 4th hours of reperfusion, also at the end of reperfusion period, plasma and tissue MPO values, MDA values, and sICAM-1 levels were detected. After sacrifice, the degree of lung injury was determined by histopathological examination. RESULTS: Compared to the control group all therapy groups showed a drastically meaningful reduction in TNF-α increase in 1, 2, and 4 hours. Plasma and lung MDA, MPO, and sICAM-1 levels were significantly lower in IL, HBO, HBO+IL, and sham groups compared with the control group. IL and/or HBO suppressed MDA and MPO increase in the lung tissue and in plasma. Additionally, histopathological score was significantly lower in HBO, IL, HBO+IL, and sham groups than that of the control group. CONCLUSION: Both HBO and IL therapy have a beneficial effect by causing a meaningful reduction in TNF-α production, MPO, MDA, sICAM-1 levels and pulmonary neutrophil sequestration; which play a role, especially, in ischemia reperfusion induced lung damage.
Acute Lung Injury*
;
Hyperbaric Oxygenation
;
Iloprost*
;
Intercellular Adhesion Molecule-1
;
Ischemia
;
Lung
;
Lung Injury
;
Malondialdehyde
;
Neutrophils
;
Oxygen*
;
Peroxidase
;
Plasma
;
Rabbits
;
Reperfusion
;
Reperfusion Injury
;
Tumor Necrosis Factor-alpha
10.Inhaled Iloprost as a First-Line Therapy for Persistent Pulmonary Hypertension of the Newborn
Seung Hyun KIM ; Hyun Ju LEE ; Nam Su KIM ; Hyun Kyung PARK
Neonatal Medicine 2019;26(4):191-197
PURPOSE: Persistent pulmonary hypertension of the newborn (PPHN) is a potentially fatal disease. Inhaled iloprost, a stable analogue of prostacyclin, has recently been used as a therapeutic option. However, there are no clinical guidelines on the use of iloprost, specifically for neonates. This study aimed to suggest the use of inhaled iloprost as a rescue therapy for PPHN based on our experience.METHODS: The efficacy and adverse events of inhaled iloprost were evaluated prospectively in nine full-term neonates with PPHN. We monitored the following parameters: fraction of inspired oxygen (FiO₂), respiratory severity score (RSS), heart rate, and mean blood pressure.RESULTS: The inhalation dose was 1 to 2 µg/kg initially, and 4 to 8 inhalations per day were applied over 2 to 8 days, except in the case of one neonate who died 2 days after birth. Echocardiographic findings, changes in FiO₂, and RSS improved within the next 7 days in eight of the nine patients. Severe side effects on heart rate and blood pressure were not observed.CONCLUSION: Our experience suggests that inhaled iloprost can be used as a first-line treatment in newborn infants with PPHN when inhaled nitric oxide is not available. To the best of our knowledge, this report is the first prospective case series on the use of inhaled iloprost in PPHN.
Blood Pressure
;
Echocardiography
;
Epoprostenol
;
Female
;
Heart Rate
;
Humans
;
Hypertension, Pulmonary
;
Iloprost
;
Infant, Newborn
;
Inhalation
;
Nitric Oxide
;
Oxygen
;
Parturition
;
Persistent Fetal Circulation Syndrome
;
Prospective Studies